CoCounsel (by Casetext) vs Lexis+ AI
Detailed side-by-side comparison to help you choose the right tool
CoCounsel (by Casetext)
🟢No CodeBusiness AI Solutions
Thomson Reuters' AI legal assistant that performs document review, contract analysis, deposition preparation, and legal research for attorneys — built on Westlaw's authoritative legal databases.
Was this helpful?
Starting Price
$225/user/monthLexis+ AI
Legal Research
AI-powered legal research platform from LexisNexis that combines generative AI with the Lexis+ content library spanning over 80 billion documents, enabling legal professionals to draft, research, summarize, and analyze legal materials with linked citations to authoritative sources.
Was this helpful?
Starting Price
CustomFeature Comparison
Scroll horizontally to compare details.
CoCounsel (by Casetext) - Pros & Cons
Pros
- ✓Backed by Thomson Reuters' authoritative Westlaw legal database — the gold standard for case law research with decades of curated content
- âś“Citation verification catches hallucinated or overruled cases that general-purpose AI tools like ChatGPT routinely miss
- âś“Legal-market-specific AI training produces more accurate results on legal tasks than general-purpose chatbots
- âś“Clio integration connects AI capabilities directly into law practice management workflows for seamless adoption
- âś“Agentic AI workflows (launched late 2025) handle multi-step legal tasks autonomously, reducing manual coordination
- âś“UK expansion in January 2026 extends coverage for firms practicing in common-law jurisdictions
Cons
- ✗Expensive at $225/user/month for Core — cost-prohibitive for many solo practitioners and small firms without high document volume
- âś—Full case law research requires a separate Westlaw Precision subscription on top of CoCounsel Core, increasing total cost significantly
- âś—Original Casetext platform was shut down in April 2025, forcing existing users through a disruptive migration
- ✗Primarily focused on US and UK law — limited usefulness for attorneys practicing in civil law or other jurisdictions
- âś—Enterprise bundle pricing is not publicly listed, requiring sales conversations that can drag on for weeks
Lexis+ AI - Pros & Cons
Pros
- âś“Grounded in over 80 billion authoritative legal documents, significantly reducing hallucination risk compared to general-purpose AI tools
- âś“Deep integration with Shepard's Citations, Lex Machina, and Practical Guidance provides end-to-end research validation and litigation analytics
- ✓Enterprise-grade security with SOC 2 Type II certification and strict data isolation—user queries and documents are not used for model training
- âś“Natural-language interface lowers the learning curve for attorneys who are not experienced with Boolean search syntax
- âś“Continuous updates and expanding jurisdiction coverage, with multilingual capabilities added through 2025
Cons
- ✗No free tier publicly available—requires a paid Lexis+ subscription (typically $150–$400/user/month) plus the AI add-on (~$100–$150/user/month), though free trial periods of 30–90 days have been reported for existing subscribers
- ✗Pricing is negotiated and not publicly listed, though industry benchmarks suggest total costs of $250–$550/user/month for individual seats, making it a significant investment for solo practitioners and small firms
- ✗Locked into the LexisNexis content ecosystem—cannot search Westlaw, Bloomberg Law, or other competing databases
- âś—AI-generated drafts still require thorough attorney review and may not capture nuanced jurisdiction-specific variations in all practice areas
- ✗Steeper total cost of ownership compared to standalone AI legal tools, as it requires a base Lexis+ subscription plus the AI add-on—though bundled pricing at higher tiers may reduce the effective premium
Not sure which to pick?
🎯 Take our quiz →Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.
Ready to Choose?
Read the full reviews to make an informed decision